As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
We are pleased to announce that Medicilon will exhibit in the EUROTOX 2024 with the Booth #43. The congress will take place from 8 to 11 September 2024 at Copenhagen, Denmark. The congress theme “Toxicology – A Quest for safe Chemicals and Medicines” reflects the congress programme including a variety of topics dealing with safety of drugs and environmental chemicals, new and emerging technologies, personalised medicine, human health effects caused by exposure to chemicals as well as safety issues arising from climate changes.
Dr. Renzong Xie, Vice President of Medicilon Quality Assurance Department, and Medicilon team will be present throughout the conference. Please stop by at our booth and discuss how Medicilon’s services and capabilities could support your research needs and expedite your drug discovery and development process.
Date: September 8-11, 2024
Location: Tivoli Congress Center, Copenhagen, Denmark
Medicilon Booth #43
Medicilon Toxicology Studies Services
Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.
As of April 2024, Medicilon has proudly served over 2000 clients worldwide, contributing to the successful approval of over 400 IND applications in China and over 70 INDs overseas, demonstrating our commitment to providing high-quality services and supporting the global advancement of pharmaceutical development.